Definitive Healthcare (NASDAQ:DH) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Definitive Healthcare (NASDAQ:DH) from a buy rating to a hold rating in a research note released on Saturday.

A number of other research firms have also recently weighed in on DH. Canaccord Genuity Group reduced their price target on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating for the company in a report on Friday. Barclays reduced their target price on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research note on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. Morgan Stanley reissued an “underperform” rating and issued a $3.50 price target on shares of Definitive Healthcare in a report on Thursday, December 18th. Finally, William Blair raised shares of Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, Definitive Healthcare currently has an average rating of “Hold” and a consensus price target of $3.52.

Definitive Healthcare Trading Down 8.6%

Shares of Definitive Healthcare stock opened at $1.28 on Friday. The firm has a 50-day simple moving average of $2.18 and a two-hundred day simple moving average of $2.87. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 1.60. Definitive Healthcare has a fifty-two week low of $1.14 and a fifty-two week high of $4.70. The company has a market cap of $180.94 million, a P/E ratio of -1.02 and a beta of 1.59.

Institutional Investors Weigh In On Definitive Healthcare

A number of large investors have recently made changes to their positions in DH. Bank of Montreal Can purchased a new position in Definitive Healthcare during the second quarter worth about $71,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Definitive Healthcare by 44.3% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 361,046 shares of the company’s stock worth $1,408,000 after buying an additional 110,894 shares during the last quarter. CWM LLC raised its position in shares of Definitive Healthcare by 212.4% during the 2nd quarter. CWM LLC now owns 24,498 shares of the company’s stock valued at $96,000 after buying an additional 16,657 shares during the period. Cambria Investment Management L.P. purchased a new stake in shares of Definitive Healthcare during the 3rd quarter valued at approximately $145,000. Finally, Ariadne Wealth Management LP acquired a new position in Definitive Healthcare in the third quarter valued at approximately $54,000. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

More Definitive Healthcare News

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q4 revenue came in roughly in-line to slightly above estimates (reported ~$61.5M vs. some analyst estimates around $59–61M), showing top-line stability versus a year ago. Read More.
• Positive Sentiment: Cash and cash equivalents increased year-over-year (reported ~$163.6M), which supports near-term liquidity. Read More.
• Neutral Sentiment: Reported GAAP EPS results were reported as meeting some consensus figures (sources show EPS in-line with a $0.06 consensus), so headline EPS didn’t surprise to the upside. Read More.
• Neutral Sentiment: Brokerage consensus has settled around a “Hold” average recommendation, reflecting mixed views across analysts. Read More.
• Negative Sentiment: The company cut guidance: Q1 FY2026 EPS guidance (~$0.03) and revenue guidance ($54M–$56M) both sit below consensus, and full‑year 2026 guidance ($0.14–$0.17 EPS; $220M–$226M revenue) also trails Street expectations — the primary driver of today’s downside. Read More.
• Negative Sentiment: Analysts lowered price targets and kept cautious ratings (Canaccord cut its target from $4.00 to $3.00 with a Hold; Stephens trimmed its target to $2.00 with Equal Weight), amplifying selling pressure. Read More.
• Negative Sentiment: Underlying profitability metrics showed deterioration in some reports (wider operating loss and larger net loss year-over-year), and multiple institutional holders trimmed positions in the latest quarter, suggesting reduced confidence from larger investors. Read More.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.